Testing a new TB drug called RESP30TB in people with newly diagnosed TB
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This trial tests a new drug, RESP30TB, to see if it is safe, tolerable, and can quickly kill TB bacteria in people with newly diagnosed, rifampicin-susceptible pulmonary TB. You may be eligible if you can produce sputum and meet other health criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have newly diagnosed TB in your lungs that is sensitive to the antibiotic rifampicin.
- You need to produce at least 10 mL of sputum (phlegm) overnight to test the drug.
- You must weigh between 88 and 198 pounds (40 to 90 kg).
- Your lung function (measured by a breathing test) must be at least 40% of normal.
- If you are HIV-positive, your CD4 count must be above 350 and you cannot be on antiviral therapy.
- You cannot be pregnant, planning pregnancy, or breastfeeding during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing new combinations of drugs to treat tuberculosis (TB) in the lungs. It aims to find a more effective and shorter treatment, and you may benefit from receiving these new drugs while helping advance TB research.
This trial tests new combinations of TB medicines for people with active lung TB that is sensitive to standard drugs. It aims to find safer, shorter treatments that work just as well or better than current options.
This Phase 2 study tests treatment for people with newly diagnosed, drug-susceptible pulmonary (lung) tuberculosis (TB). It aims to see whether the study treatment works well and is safe for curing TB.
This trial tests a new “triple-dose” set of medicines to treat people whose tuberculosis (TB) has come back in the lungs. If you qualify, the goal is to improve cure rates and reduce the chance of TB returning again.
This trial studies whether a rifapentine-based TB regimen can work just as well while shortening treatment time. It’s for people with rifampicin-sensitive, smear-positive lung tuberculosis.
This study tests personalized TB treatment schedules based on your individual risk factors. Researchers want to see if matching treatment intensity to your specific situation helps cure TB while minimizing side effects.
Hear when a new Pulmonary Tuberculoses trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.